Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Read more
(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more
Dec 9 (Reuters) - The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.
Read moreDec 9 (Reuters) - The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.
Read more(Alliance News) - Daiichi Sankyo Co Ltd on Friday said updated results from a phase 1 trial showed datopotamab deruxtecan continued to show promising responses in patients with breast cancer.
Read more(Correcting date of announcement to Thursday.)
Read more(Alliance News) - AstraZeneca PLC on Friday announced that datopotamab deruxtecan has shown "encouraging and durable efficacy" in phase 1 trials.
Read more(Sharecast News) - AstraZeneca said on Thursday that a phase III trial of its capivasertib drug in combination with Faslodex (fulvestrant) had demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
Read more(Alliance News) - AstraZeneca PLC on Thursday releases results from trials on its breast cancer drugs camizestrant and capivasertib, both when compared to faslodex, which treats breast cancer.
Read more(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a raft of economic data from both China and Europe.
Read more(Alliance News) - AstraZeneca PLC on Wednesday said its Enhertu drug achieved statistically significant overall survival in breast cancer patients in a recent trial.
Read more(Alliance News) - Stocks in Europe were mostly in the red on Wednesday, as economic data from China stoked fear of a global slowdown, while the FTSE 100 was spared a steeper decline thanks to gains by pharmaceutical stocks.
Read more(Alliance News) - Stock prices in London mostly opened flat on Wednesday, with falls in FTSE 100 housebuilders, miners and oil majors offset by gains for pharmaceuticals as GSK shook off Zantac litigation.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more
Last checked at